A phase 2 study of sorafenib (BAY 43-9006) in metastatic renal cell cancer to the brain
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2013
At a glance
- Drugs Sorafenib (Primary)
- Indications Cancer metastases; Renal cell carcinoma
- Focus Therapeutic Use
- 22 Apr 2008 The expected completion date for this trial is now 1 Jun 2007.
- 16 Apr 2008 Status changed from in progress to completed.
- 10 Aug 2006 New trial record.